标题
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
作者
关键词
-
出版物
Current Obesity Reports
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-03
DOI
10.1007/s13679-022-00474-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
- (2021) Chloe Wong et al. Frontiers in Endocrinology
- Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
- (2021) Masato Yoneda et al. BMJ Open Diabetes Research & Care
- Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
- (2021) Caiyun Zheng et al. Cardiovascular Diabetology
- Clinical Adverse Events Associated with Sodium–Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals
- (2021) Donna Shu-Han Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
- (2021) Stergios A. Polyzos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
- (2021) Abdul M. Majzoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
- (2021) Evangelia S. Makri et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
- (2021) Mathies M. Jepsen et al. EXPERT OPINION ON EMERGING DRUGS
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial Effects of Glucagon-Like Peptide 1 Receptor Agonists on Glucose Control, Cardiovascular Risk Profile, and Non-Alcoholic Fatty Liver Disease. An Expert Opinion of the Italian Diabetes Society
- (2021) Raffaele Napoli et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Pharmacotherapy of obesity: An update
- (2021) Andrea Cignarella et al. PHARMACOLOGICAL RESEARCH
- Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
- (2021) Yi-Zhou Huang et al. World Journal of Diabetes
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cilofexor for the treatment of nonalcoholic steatohepatitis
- (2021) Stergios A. Polyzos et al. Current Vascular Pharmacology
- Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
- (2021) Nick Finer DIABETES OBESITY & METABOLISM
- Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
- (2021) Cheng Han Ng et al. Endocrine Practice
- Nonalcoholic fatty liver disease: lifestyle and quality of life
- (2021) Ilias Vachliotis et al. Hormones-International Journal of Endocrinology and Metabolism
- A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
- (2021) Samit Ghosal et al. Scientific Reports
- A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men
- (2021) Naoko Nakanishi et al. Scientific Reports
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- (2020) Emmanuel Somm et al. Translational Research
- Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
- (2020) Francisca dos Santos Coelho et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map
- (2020) Jai Kumar et al. DIGESTIVE AND LIVER DISEASE
- Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
- (2020) Evangelia Makri et al. ARCHIVES OF MEDICAL RESEARCH
- Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials
- (2020) Harpreet S. Bajaj et al. DIABETES OBESITY & METABOLISM
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial
- (2019) Dario Tuccinardi et al. DIABETES OBESITY & METABOLISM
- Epidemiology of chronic liver diseases in the USA in the past three decades
- (2019) Zobair M Younossi et al. GUT
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
- (2019) Vasiliki Venetsanaki et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?
- (2018) Stergios A. Polyzos et al. HEPATOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Pharmacotherapy of type 2 diabetes: An update
- (2018) Jagriti Upadhyay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
- (2018) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes
- (2018) H.S. Bajaj et al. DIABETES & METABOLISM
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
- (2018) Simona Leoni et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- (2018) Francesco Bifari et al. PHARMACOLOGICAL RESEARCH
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups
- (2017) Shiv Chitturi et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
- (2016) Takamasa Ohki et al. CLINICAL DRUG INVESTIGATION
- Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
- (2016) William N. Hannah et al. Clinics in Liver Disease
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) et al. DIABETOLOGIA
- Emerging and future therapies for nonalcoholic steatohepatitis in adults
- (2016) Gesthimani Mintziori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Nonalcoholic fatty future disease
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies
- (2016) L. Li et al. Obesity Reviews
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2015) Laura J Carbone et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Nonalcoholic Fatty Liver Disease
- (2012) Stergios A. Polyzos et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
- (2010) Patrick R Kenny et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: An Endocrine Society Clinical Practice Guideline
- (2010) David Heber et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
- (2009) Stergios A. Polyzos et al. DIABETES OBESITY & METABOLISM
- Orlistat-Associated Adverse Effects and Drug Interactions
- (2009) Theodosios D Filippatos et al. DRUG SAFETY
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
- (2009) Prospective Studies Collaboration LANCET
- Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
- (2008) Stephen A. Harrison et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search